NCT05052710View on ClinicalTrials.gov

Study to Assess the Effect of AZD4831 on the Pharmacokinetics (Drug Behavior in the Body) of Midazolam

PHASE1CompletedINTERVENTIONAL

Enrollment

14

Participants

Timeline

Start Date

October 5, 2021

Primary Completion Date

November 29, 2021

Study Completion Date

November 29, 2021

Conditions

Healthy Volunteers

Interventions

DRUG

AZD4831

Subjects will receive oral doses once daily from Days 2-11.

DRUG

Midazolam

Subjects will receive oral single doses on Day 1 and Day 11.

Trial Locations (1)

HA1 3UJ

Research Site, Harrow

Sponsors

Lead Sponsor

All Listed Sponsors

lead

AstraZeneca

INDUSTRY